Baxter International Inc. (NYSE:BAX) Files An 8-K Other Events
Item8.01
| Other Events. |
On May30, 2017, Baxter International Inc. (the Company) completed
a public offering of 600,000,000 aggregate principal amount of
its 1.300% Senior Notes due 2025 (the Notes). The Notes were sold
to an Underwriting Agreement, dated as of May19, 2017, among the
Company, Deutsche Bank AG, London Branch, Goldman Sachs Co. LLC,
J.P. Morgan Securities plc and the other underwriters named
therein. The offering and sale of the Notes was registered under
the Registration Statement (the Registration Statement) on Form
S-3 (Registration No.333-207810) that the Company filed with the
Securities and Exchange Commission on November4, 2015 and
supplemented by the prospectus supplement dated May19, 2017 and
filed with the Securities and Exchange Commission on May22, 2017.
The Notes were issued to, and are governed by the terms of, an
Indenture, dated as of August8, 2006, by and between the Company
and The Bank of New York Mellon Trust Company, N.A. (as successor
in interest to J.P. Morgan Trust Company, National Association),
as trustee (the Trustee), as amended and supplemented by the
Eleventh Supplemental Indenture, dated as of May30, 2017, by and
between the Company and the Trustee.
The Company is filing the exhibits attached to this Current
Report on Form 8-K in connection with the Registration Statement.
| Item9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
|
Exhibit No. |
Description |
|
| 1.1 |
Underwriting Agreement, dated as of May19, 2017, by and among the Company, Deutsche Bank AG, London Branch, Goldman Sachs Co. LLC, J.P. Morgan Securities plc and the other underwriters named therein |
|
| 4.1 |
Indenture, dated as of August8, 2006, by and between the Company and The Bank of New York Mellon Trust Company, N.A. (as successor in interest to J.P. Morgan Trust Company, National Association), as Trustee (incorporated by reference to Exhibit 4.1 to the Companys Current Report on Form 8-K, filed on August9, 2006) |
|
| 4.2 |
Eleventh Supplemental Indenture, dated as of May30, 2017, by and between the Company and The Bank of New York Mellon Trust Company, N.A., as Trustee (including form of 1.300% Senior Notes due 2025) |
|
| 5.1 | Opinion of Ellen K. McIntosh | |
| 23.1 | Consent of Ellen K. McIntosh (included in Exhibit 5.1) |
About Baxter International Inc. (NYSE:BAX)
Baxter International Inc., through its subsidiaries, provides a portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics, and pharmacy automation, software and services. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures IV solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, inhalation anesthetics, and biosurgery products. The business also provides products and services related to pharmacy compounding, and drug formulation. The Renal business provides products and services to treat end-stage renal disease, or irreversible kidney failure and acute kidney injuries. Baxter International Inc. (NYSE:BAX) Recent Trading Information
Baxter International Inc. (NYSE:BAX) closed its last trading session down -0.50 at 58.64 with 2,014,609 shares trading hands.
